All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Patients with multiple myeloma (MM) often experience multiple recurrent episodes of remission and relapse. The acquisition of resistance results in the lack of response to treatment or the response being diminished over time. Some tumors can become cross-resistant to a wide range of unrelated drugs. Such multidrug resistance (MDR), following exposure to a single chemotherapeutic agent, is often linked to the overexpression of plasma membrane drug efflux transporters, like P-glycoprotein (P-gp). In order to increase the chances of a positive MM treatment outcome with not only chemotherapeutic agents but also immunomodulatory drugs and proteasome inhibitors, it is important to continuously monitor for the presence and development of MDR during therapy.
One of the less invasive ways for such monitoring could potentially be testing of patients’ blood samples for the presence of circulating cancer-derived microparticles (MPs), a subset of extracellular vesicles. Levels of CD138+ circulating MPs have been shown to be elevated in patients with MM across all stages of the disease and correlate with plasma-cell burden and treatment response. However, currently, there is a lack of reliable tests that would allow for direct, continuous monitoring of MDR in MM.
Sabna Rajeev Krishnan and colleagues developed a novel blood test that could be used during routine follow-up to continuously monitor patients for the presence of MDR during treatment, and assess tumor burden.1 The article below provides a summary of the data published in the Blood Cancer Journal.
This study demonstrated that circulating MPs can be used to detect and monitor MDR in patients with MM, acting as a surrogate marker of their cells of origin. Elevated levels of P-gp+ and PS+ MPs were found to correlate with disease progression and treatment unresponsiveness. Moreover, dual positive CD138−P-gp+CD34+ MPs were associated with aggressive and unresponsive disease.
The low invasiveness of this personalized liquid biopsy test makes it feasible for the continuous monitoring of resistance. The authors believe that this new test could complement existing procedures used for the management of patients with MM. The study is the first one to demonstrate the presence of P-gp on the surface of MPs in cancer.
Rajeev Krishnan S, De Rubis G, Suen H, et al. A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma. Blood Cancer J. 2020;10(3):37. DOI: 10.1038/s41408-020-0304-7
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox